Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Taysha Gene Thera5, Inc. (TSHA) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Taysha Gene Thera5, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1806310.
Total stock buying since 2021: $26,756,723.
Total stock sales since 2021: $1,693,513.
Total stock option exercises since 2021: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 750,000 | $2,062,500 | 111,545 | $317,902 | 0 | $0 |
| 2024 | 1,333,333 | $2,999,999 | 0 | $0 | 0 | $0 |
| 2023 | 17,905,000 | $16,186,398 | 582,095 | $465,671 | 0 | $0 |
| 2022 | 1,714,602 | $4,675,249 | 95,000 | $348,264 | 0 | $0 |
| 2021 | 65,890 | $832,577 | 33,000 | $561,676 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 111,545 | $317,902 | 0 | $0 |
| 2025-05 | 750,000 | $2,062,500 | 0 | $0 | 0 | $0 |
| 2024-06 | 1,333,333 | $2,999,999 | 0 | $0 | 0 | $0 |
| 2023-11 | 100,000 | $163,000 | 0 | $0 | 0 | $0 |
| 2023-08 | 17,800,000 | $16,019,998 | 33,000 | $76,890 | 0 | $0 |
| 2023-07 | 0 | $0 | 85,872 | $60,753 | 0 | $0 |
| 2023-06 | 0 | $0 | 463,223 | $328,028 | 0 | $0 |
| 2023-05 | 5,000 | $3,400 | 0 | $0 | 0 | $0 |
| 2022-10 | 1,500,000 | $3,000,000 | 0 | $0 | 0 | $0 |
| 2022-08 | 0 | $0 | 32,000 | $117,535 | 0 | $0 |
| 2022-07 | 0 | $0 | 36,784 | $132,097 | 0 | $0 |
| 2022-06 | 0 | $0 | 26,216 | $98,632 | 0 | $0 |
| 2022-02 | 214,602 | $1,675,249 | 0 | $0 | 0 | $0 |
| 2021-11 | 64,720 | $806,428 | 0 | $0 | 0 | $0 |
| 2021-08 | 0 | $0 | 33,000 | $561,676 | 0 | $0 |
| 2021-05 | 1,170 | $26,149 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-21 | Alam Kamran (CHIEF FINANCIAL OFFICER) | Sale | 54,491 | 2.85 | 155,299 |
| 2025-08-21 | Nagendran Sukumar (President and Head of R&D) | Sale | 57,054 | 2.85 | 162,603 |
| 2025-05-30 | Manning Paul B | Buy | 750,000 | 2.75 | 2,062,500 |
| 2024-06-27 | Manning Paul B | Buy | 1,333,333 | 2.25 | 2,999,999 |
| 2023-11-17 | Manning Paul B (10% Owner) | Buy | 100,000 | 1.63 | 163,000 |
| 2023-08-24 | Alam Kamran (Chief Financial Officer) | Sale | 33,000 | 2.33 | 76,890 |
| 2023-08-16 | Stalfort John A Iii (Director) | Buy | 777,778 | .90 | 700,000 |
| 2023-08-16 | Nolan Sean P. (Chief Executive Officer) | Buy | 444,444 | .90 | 399,999 |
| 2023-08-16 | Manning Paul B (10% Owner) | Buy | 16,466,667 | .90 | 14,820,000 |
| 2023-08-16 | Donenberg Phillip B. (Director) | Buy | 111,111 | .90 | 99,999 |
| 2023-07-13 | Session R.a. Ii | Sale | 5,344 | .70 | 3,740 |
| 2023-07-12 | Session R.a. Ii | Sale | 80,528 | .71 | 57,013 |
| 2023-06-23 | Session R.a. Ii (10% Owner) | Sale | 18,100 | .70 | 12,742 |
| 2023-06-22 | Session R.a. Ii (10% Owner) | Sale | 10,508 | .70 | 7,387 |
| 2023-06-21 | Session R.a. Ii (10% Owner) | Sale | 138,962 | .70 | 97,690 |
| 2023-06-20 | Session R.a. Ii (10% Owner) | Sale | 295,653 | .71 | 210,209 |
| 2023-05-16 | Nagendran Sukumar (President and Head of R&D) | Buy | 5,000 | .68 | 3,400 |
| 2022-10-31 | Manning Paul B (Director) | Buy | 1,500,000 | 2.00 | 3,000,000 |
| 2022-08-23 | Alam Kamran (Chief Financial Officer) | Sale | 3,325 | 3.47 | 11,537 |
| 2022-08-22 | Alam Kamran (Chief Financial Officer) | Sale | 9,717 | 3.50 | 34,009 |
| 2022-08-19 | Alam Kamran (Chief Financial Officer) | Sale | 11,482 | 3.75 | 43,057 |
| 2022-08-18 | Alam Kamran (Chief Financial Officer) | Sale | 7,476 | 3.87 | 28,932 |
| 2022-07-06 | Prasad Suyash (CMO and Head of R&D) | Sale | 8,956 | 3.79 | 33,943 |
| 2022-07-05 | Prasad Suyash (CMO and Head of R&D) | Sale | 3,905 | 3.51 | 13,706 |
| 2022-07-01 | Prasad Suyash (CMO and Head of R&D) | Sale | 23,923 | 3.53 | 84,448 |
| 2022-06-30 | Prasad Suyash (CMO and Head of R&D) | Sale | 13,892 | 3.72 | 51,678 |
| 2022-06-29 | Prasad Suyash (CMO and Head of R&D) | Sale | 12,324 | 3.81 | 46,954 |
| 2022-02-03 | Manning Paul B (Director) | Buy | 76,602 | 7.84 | 600,559 |
| 2022-02-02 | Nagendran Sukumar (Director) | Buy | 10,000 | 8.01 | 80,100 |
| 2022-02-02 | Manning Paul B (Director) | Buy | 125,000 | 7.77 | 971,250 |
| 2022-02-02 | Donenberg Phillip B. (Director) | Buy | 3,000 | 7.78 | 23,340 |
| 2021-11-24 | Manning Paul B (Director) | Buy | 2,202 | 13.19 | 29,044 |
| 2021-11-23 | Session R.a. Ii (President and CEO) | Buy | 42,518 | 12.38 | 526,585 |
| 2021-11-23 | Manning Paul B (Director) | Buy | 20,000 | 12.54 | 250,799 |
| 2021-08-20 | Alam Kamran (Chief Financial Officer) | Sale | 11,840 | 16.92 | 200,332 |
| 2021-08-19 | Alam Kamran (Chief Financial Officer) | Sale | 9,967 | 16.77 | 167,146 |
| 2021-08-18 | Alam Kamran (Chief Financial Officer) | Sale | 11,193 | 17.35 | 194,198 |
| 2021-05-20 | Nolan Sean P. (Director) | Buy | 1,170 | 22.35 | 26,149 |
Insider trading activities including stock purchases, stock sales, and option exercises of TSHA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Taysha Gene Thera5, Inc. (symbol TSHA, CIK number 1806310) see the Securities and Exchange Commission (SEC) website.